Open Access

Poster Session 2 - Drug treatment for atrial fibrillation

Event: ESC CONGRESS 2019
Topic: European Society of Cardiology
Session type: Poster Session
Date: 1 September 2019

Session

10 presentations in this session

Prevalence and risk of DOACs inappropriate dosing in atrial fibrillation. An analysis of the Swiss-AF and BEAT-AF registries

Speaker: Doctor G. Montrasio (Zurich, CH)
Thumbnail

Heparin and low-molecular-weight heparin switch associated with an increase in bleeding complications in patients on apixaban undergoing catheter ablation: The AMPER ABLATION study

Speaker: Doctor W. Amara (Le Raincy-Montfermeil, FR)
Thumbnail

Amiodarone treatment duration and reasons for permanent drug discontinuation in patients with atrial fibrillation

Speaker: Doctor M. Mihajlovic (Belgrade, RS)
Thumbnail

Use of direct thrombin inhibitor on the day of atrial fibrillation ablation decreases incidence of silent cerebral ischemia detected by magnetic resonance imaging

Speaker: Associate Professor M. Harada (Toyoake, JP)
Thumbnail

Comparison of efficacy of different anticoagulation strategies used during pulmonary vein isolation in left atrial blood samples

Speaker: Doctor O. Hajas (Debrecen, HU)
Thumbnail

Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials

Speaker: Professor H. Crijns (Maastricht, NL)
Thumbnail

Oral anticoagulation in patients undergoing elective cardioversion of atrial fibrillation. Real-life experience from Finland

Speaker: Mrs S. Itainen-Stromberg (Helsinki, FI)
Thumbnail

Propofol suppresses atrial fibrillation in an experimental whole-heart model

Speaker: Doctor J. Wolfes (Munster, DE)
Thumbnail

Modified frailty as a novel factor to predict the effectiveness of electrical cardioversion of atrial fibrillation in the elderly population

Speaker: Associate Professor A. Mlynarska (Katowice, PL)
Thumbnail

Propensity score matched analysis of antazoline mesylate vs. amiodarone or propafenone for pharmacological cardioversion of short-duration atrial fibrillation

Speaker: Associate Professor M. Wybraniec (Katowice, PL)
Thumbnail

10 speakers from this session

Doctor Giulia Montrasio

University Hospital Zurich, Zurich (Switzerland)
0 follower

Doctor Walid Amara

Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Le Raincy-Montfermeil (France)
1 presentation
0 follower

Doctor Miroslav Mihajlovic

University Clinical Center of Serbia, Belgrade (Serbia)
0 follower

Associate Professor Masahide Harada

Fujita Health University, Toyoake (Japan)
0 follower

Doctor Orsolya Hajas

University of Debrecen, Debrecen (Hungary)
0 follower

Professor Harry Crijns

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))
17 presentations
0 follower

Mrs Saga Itainen-Stromberg

Helsinki University Hospital, Helsinki (Finland)
0 follower

Doctor Julian Wolfes

University Hospital of Munster, Munster (Germany)
0 follower

Associate Professor Agnieszka Mlynarska

Slaski Uniwersytet Medyczny w Katowicach, Katowice (Poland)
0 follower

Associate Professor Maciej Wybraniec

School of Medicine in Katowice, Medical University of Silesia, Katowice (Poland)
0 follower

This platform is supported by

logo Novo Nordisk